DE68924183D1 - Zusammensetzung und Verfahren zum Schutz gegen durch Mikroorganismen verursachte Krankheiten. - Google Patents

Zusammensetzung und Verfahren zum Schutz gegen durch Mikroorganismen verursachte Krankheiten.

Info

Publication number
DE68924183D1
DE68924183D1 DE68924183T DE68924183T DE68924183D1 DE 68924183 D1 DE68924183 D1 DE 68924183D1 DE 68924183 T DE68924183 T DE 68924183T DE 68924183 T DE68924183 T DE 68924183T DE 68924183 D1 DE68924183 D1 DE 68924183D1
Authority
DE
Germany
Prior art keywords
nuclease
microorganisms
composition
protection against
diseases caused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68924183T
Other languages
English (en)
Other versions
DE68924183T2 (de
Inventor
Daryl Faulds
Mimi Vishoot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ml Technology Ventures Lp New York Ny Us
ML Technology Ventures LP
Original Assignee
Ml Technology Ventures Lp New York Ny Us
ML Technology Ventures LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ml Technology Ventures Lp New York Ny Us, ML Technology Ventures LP filed Critical Ml Technology Ventures Lp New York Ny Us
Application granted granted Critical
Publication of DE68924183D1 publication Critical patent/DE68924183D1/de
Publication of DE68924183T2 publication Critical patent/DE68924183T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/87—Mycoplasma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Fodder In General (AREA)
DE68924183T 1988-01-20 1989-01-17 Zusammensetzung und Verfahren zum Schutz gegen durch Mikroorganismen verursachte Krankheiten. Expired - Fee Related DE68924183T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/146,256 US4985243A (en) 1988-01-20 1988-01-20 Composition and method for protecting against diseases caused by microorganisms

Publications (2)

Publication Number Publication Date
DE68924183D1 true DE68924183D1 (de) 1995-10-19
DE68924183T2 DE68924183T2 (de) 1996-03-21

Family

ID=22516535

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68924183T Expired - Fee Related DE68924183T2 (de) 1988-01-20 1989-01-17 Zusammensetzung und Verfahren zum Schutz gegen durch Mikroorganismen verursachte Krankheiten.

Country Status (11)

Country Link
US (1) US4985243A (de)
EP (1) EP0325191B1 (de)
JP (1) JPH0768142B2 (de)
AT (1) ATE127693T1 (de)
DE (1) DE68924183T2 (de)
DK (1) DK22389A (de)
ES (1) ES2078900T3 (de)
GR (1) GR3017427T3 (de)
IE (1) IE890141L (de)
PT (1) PT89488A (de)
ZA (1) ZA89447B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5240706A (en) * 1989-04-07 1993-08-31 Ml Technology Ventures, L.P. Intranasal administration of Mycoplasma hyopneumoniae antigen
DE69128361T3 (de) * 1990-05-29 2006-04-13 Wyeth Holdings Corp. Impfstoff gegen die pneumonie bei schweinen und verfahren zu seiner herstellung
US6113916A (en) * 1990-05-29 2000-09-05 American Cyanamid Company Method of enhancing cell mediated immune responses
US5565205A (en) * 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
US5338543A (en) * 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
USRE39494E1 (en) * 1992-02-27 2007-02-27 Intervet Inc. Inactivated mycoplasma hyopneumoniae and uses therefor
ATE273022T1 (de) * 1992-09-28 2004-08-15 Wyeth Corp Verfahren zur verstärkung zellularer immunantworten
US5498527A (en) * 1994-02-18 1996-03-12 Ube Industries, Ltd. Phosphorylcholine-containing glyceroglycolipid
AU2003298972A1 (en) * 2003-07-14 2005-02-04 Dmitry Dmitrievich Genkin Method for treating oncological, virulent and somatic diseases, method for controlling treatment efficiency, pharmaceutical agents and composition for carrying out said treatment
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8916151B2 (en) 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
AU2006289626A1 (en) * 2005-09-09 2007-03-15 Universitat Zurich Antigens for vaccination against and detection of Mycoplasma suis
PL2095825T3 (pl) 2006-11-28 2011-12-30 Cls Therapeutics Ltd Sposób leczenia ludzkich chorób związanych ze zwiększoną zawartością kwasu deoksyrybonukleinowego w przestrzeniach pozakomórkowych i tkankach i preparat leczniczy do przeprowadzenia tego sposobu
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
CN104784465B (zh) * 2015-04-14 2017-11-03 中国农业科学院兰州畜牧与兽药研究所 一种用于防治猪气喘病的中药组合物及其制备方法和应用
US11701410B2 (en) 2015-05-22 2023-07-18 Cls Therapeutics Limited Extracellular DNA as a therapeutic target in neurodegeneration
JP2021510539A (ja) 2018-01-16 2021-04-30 シーエルエス セラピューティクス リミテッドＣＬＳ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ デオキシリボヌクレアーゼ（ＤＮａｓｅ）活性を有する酵素の肝臓発現による疾患の処置
CN109234253B (zh) * 2018-09-19 2021-02-19 中国农业大学 Mhp非特异性核酸酶及其编码基因与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3485721A (en) * 1968-04-24 1969-12-23 Merck & Co Inc Process for growing mycoplasma pneumonial organisms
US4123427A (en) * 1976-07-27 1978-10-31 Daniel Thomas M Method for the purification of mycobacterial protein antigens and resulting product
FR2565825B1 (fr) * 1984-06-15 1990-07-13 Centre Nat Rech Scient Vaccin contre les maladies dues a des microorganismes tels que des mycoplasmes, sa preparation et membranes de microorganismes en tant que principe actif
US4666851A (en) * 1985-04-25 1987-05-19 Lee Sin H Specific mycoplasma membrane antigen and antibody and their clinical applications

Also Published As

Publication number Publication date
PT89488A (pt) 1989-10-04
JPH0768142B2 (ja) 1995-07-26
US4985243A (en) 1991-01-15
DE68924183T2 (de) 1996-03-21
DK22389A (da) 1989-07-21
DK22389D0 (da) 1989-01-19
GR3017427T3 (en) 1995-12-31
ATE127693T1 (de) 1995-09-15
EP0325191B1 (de) 1995-09-13
EP0325191A2 (de) 1989-07-26
ZA89447B (en) 1989-10-25
EP0325191A3 (en) 1990-04-04
JPH02711A (ja) 1990-01-05
ES2078900T3 (es) 1996-01-01
IE890141L (en) 1989-07-20

Similar Documents

Publication Publication Date Title
ATE127693T1 (de) Zusammensetzung und verfahren zum schutz gegen durch mikroorganismen verursachte krankheiten.
ATE131161T1 (de) Substanz pf 1022, verfahren zu ihrer herstellung und diese substanz enthaltende anthelmintische zusammensetzung.
SE9600406D0 (sv) Novel coompounds
ATE197765T1 (de) Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
DE69536039D1 (de) Wirtszelle enthaltend ein rekombinantes Virus, welches ein Antigen exprimiert und ein rekombinantes Virus, welches ein immunstimulatorisches Molekül exprimiert
ATE153332T1 (de) Verfahren zur herstellung von oxetanonen
DE69837041D1 (de) Verfahren und mikroorganism zur herstellung von purin-nukleosiden durch fermentation
DE69527429T2 (de) Verfahren zur herstellung von wasserfreien und hydrat-formen von antihistaminischen piperinderivaten, polymerphe und pseudomorphe davon
ATE219499T1 (de) Lipopeptid-derivate, verfahren zu ihrer herstellung und ihre verwendung
FI952148A (fi) Geenitekninen menetelmä ja isäntä ksylitolin valmistamiseksi
DE69132276T2 (de) Verfahren zur herstellung von nukleotiden
PL300327A1 (en) Substituted cycolohexane derivatives, method of obtaining them and application of these compounds in treating diseases
ATE86978T1 (de) Verfahren zur herstellung von 3,5-dimethyl-4methoxypyridinderivaten sowie neues zwischenprodukt hierfuer.
DE69513847T2 (de) Verfahren zur herstellung von substituierten 3-aminobenzonitrilen
ATE14126T1 (de) Verfahren zur herstellung von 2-acyl1,3,4,6,7,11b-2h-hexahydro-4-pyrazino(2,1a)isochinolinonen und zwischenprodukte.
ATE236895T1 (de) Ringannelierte dihydropyrane, verfahren zur herstellung sowie deren verwendung
DE69025375D1 (de) Verfahren
DE69812079D1 (de) Verfahren zur herstellung eines buthylthuio-isochinolinderivates und zwischenprodukte dafür
ATE161051T1 (de) Verfahren zur herstellung aktivierter sialinsäuren
ATE7700T1 (de) 2-hydroxy-1,2,4-butantricarbonsaeure-oligoribosi - derivate, verfahren zu ihrer herstellung und ihre verwendung als prophylaktische mittel gegen zahnkaries.
ATE27281T1 (de) Verfahren zur herstellung von oxanosin.
ATE156132T1 (de) Verfahren zur herstellung von pipazetat

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee